Key Developments: Opexa Therapeutics Inc (OPXA.PH)

OPXA.PH on Philadelphia Stock Exchange

1.60USD
28 Jul 2014
Price Change (% chg)

$-0.08 (-4.76%)
Prev Close
$1.68
Open
$1.60
Day's High
$1.60
Day's Low
$1.60
Volume
200
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Latest Key Developments (Source: Significant Developments)

Opexa Therapeutics Inc announces closing of public offering of common stock
Monday, 23 Dec 2013 10:18am EST 

Opexa Therapeutics Inc:Says the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock.Says it also including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share.Says gross proceeds to Opexa from this offering were $8,054,600, before deducting underwriting discounts and commissions and other estimated offering expenses and including the full exercise of the over-allotment option.Says it intends to use the net proceeds from the offering to continue funding the ongoing Abili-T clinical study of Tcelna in patients with Secondary Progressive MS and for general corporate purposes.Says Aegis Capital Corp. acted as sole book-running manager for the offering.  Full Article

Opexa Therapeutics Inc announces pricing of public offering of common stock
Tuesday, 17 Dec 2013 09:15pm EST 

Opexa Therapeutics Inc:Prices an underwritten public offering of 4.12 million shares of its common stock at a price to the public of $1.70 per share.Says the gross proceeds to Opexa from this offering are expected to be about $7 mln.Says all of the shares in the offering are to be sold by Opexa.Says it has also granted the underwriters a 45-day option to purchase up to an additional 618,000 shares of common stock to cover over-allotments, if any.Says offering is expected to close on or about Dec. 23.Says it intends to use the net proceeds from the offering to continue funding the ongoing Abili-T clinical study of Tcelna in patients with Secondary Progressive MS and for general corporate purposes.Says Aegis Capital Corp. is acting as sole book-running manager in this offering.  Full Article

Opexa Therapeutics Inc announces proposed public offering of common stock
Tuesday, 17 Dec 2013 04:33pm EST 

Opexa Therapeutics Inc:Says it intends to offer shares of its common stock in an underwritten secondary public offering.Says all of the shares in the offering are to be sold by Opexa.Says it intends to use the net proceeds from the offering to continue funding the ongoing Abili-T clinical study of Tcelna in patients with Secondary Progressive MS and for general corporate purposes.Says Aegis Capital Corp. is acting as sole book-running manager in this offering.  Full Article

Opexa Therapeutics Inc Announces Closing of Partial Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
Wednesday, 4 Sep 2013 10:42am EDT 

Opexa Therapeutics Inc announced the closing of the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 650,000 shares of its common stock, at a price to the public of $1.50 per share, in connection with the Company`s recently announced underwritten public offering of 12,000,000 shares of common stock, bringing total gross proceeds from the offering to $18,975,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Aegis Capital Corp. acted as sole book-running manager for the offering.  Full Article

Opexa Therapeutics Inc Announces Closing Of Public Offering Of Common Stock
Tuesday, 13 Aug 2013 11:12am EDT 

Opexa Therapeutics Inc announced that the closing of the previously announced underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this offering were $18 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by Opexa. Opexa has also granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock to cover over-allotments, if any. Opexa intends to use the net proceeds from the offering to fund further clinical development of Tcelna in an ongoing Phase IIb clinical study of patients with Secondary Progressive MS as well as the expenses of its operations during such development and for general corporate purposes. Opexa may also use a portion of the net proceeds to repay all or a portion of its outstanding convertible secured promissory notes. Aegis Capital Corp. acted as sole book-running manager for the offering.  Full Article

Opexa Therapeutics Inc Announces Pricing Of Public Offering Of Common Stock
Wednesday, 7 Aug 2013 09:09pm EDT 

Opexa Therapeutics Inc announced the pricing of an underwritten public offering of 12 million shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this offering are expected to be approximately $18 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Opexa. Opexa has also granted the underwriters a 30-day option to purchase up to an additional 1.8 million shares of common stock to cover over-allotments, if any. The offering is expected to close on or about August 13, 2013. .  Full Article

Opexa Therapeutics Inc Announces Changes To Senior Management Team
Monday, 1 Apr 2013 09:00am EDT 

Opexa Therapeutics Inc announced the strengthening of its management team through the appointment of several key individuals. Karthik Radhakrishnan has been appointed Chief Financial Officer, Kenny Frazier has been appointed Vice President of Clinical Development and Regulatory Affairs and Maryann Murray has been appointed as Clinical Development Manager.  Full Article

Opexa Therapeutics Inc Announces Pricing Of Common Stock And Warrant Offering
Thursday, 7 Feb 2013 09:00am EST 

Opexa Therapeutics Inc announced that it has priced an offering of shares of its common stock and warrants to purchase common stock in a private registered offering of 1,083,334 units at a price of $3.00 per unit, for gross proceeds of $3,250,000. Each unit consists of one share of common stock and a warrant to purchase one-half (0.50) of a share of common stock. The shares of common stock and warrants are immediately separable and will be issued separately such that no units will be issued. The warrants are exercisable immediately upon issuance, have a four-year term and an exercise price of $3.00 per share. The offering is expected to close on or about February 11, 2013, subject to customary closing conditions. All of the shares in the offering are to be sold by Opexa.The net proceeds from these financing arrangements will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's ongoing Phase 2b clinical trial of Tcelna in Secondary Progressive MS patients. Dawson James Securities, Inc. acted as exclusive placement agent in connection with the offering.  Full Article

Merck Serono and Opexa Therapeutics Inc Enter Into Option And License Agreement For Development Of Tcelna For Treatment Of Multiple Sclerosis
Tuesday, 5 Feb 2013 07:30am EST 

Opexa Therapeutics Inc announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna (imilecleucel-T), a potential personalized T-cell therapy for patients suffering from multiple sclerosis. Tcelna (imilecleucel-T) is being developed by Opexa and is in a Phase IIb clinical trial in patients with Secondary Progressive MS (SPMS). Potential payments to Opexa from the option and license agreement could total $225 million based upon the development and commercialization of Tcelna for MS.  Full Article

Opexa Therapeutics Inc Closes Private Note Offering
Wednesday, 23 Jan 2013 05:15pm EST 

Opexa Therapeutics Inc announced that the closing of a private offering of unsecured convertible promissory notes and warrants to purchase shares of common stock for gross proceeds of $650,000. Opexa expects to use proceeds from the financing to continue its Phase IIb clinical study of Tcelna in patients with Secondary Progressive MS (SP-MS) and general corporate purposes. Participating in the financing were new investors and existing shareholders, including a member of Opexa`s Board of Directors.  Full Article

Search Stocks